LesinskiLab
@lesinskilab.bsky.social
The Lesinski Laboratory is focused on understanding the interactions between the immune system and cancer. opinions are my own. #immunotherapy #GICancer
Reposted by LesinskiLab
🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity
Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host
B cells and drive B cell proliferation and differentiation. These Th17 cells require
B cells for sustained immunit...
www.cell.com
July 25, 2025 at 2:51 PM
🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models!
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!
pubmed.ncbi.nlm.nih.gov/40590857/
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!
pubmed.ncbi.nlm.nih.gov/40590857/
Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed
These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...
pubmed.ncbi.nlm.nih.gov
July 3, 2025 at 1:06 PM
Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models!
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!
pubmed.ncbi.nlm.nih.gov/40590857/
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!
pubmed.ncbi.nlm.nih.gov/40590857/
Cool pre-print alert! insight into how neoAg alter trafficking of adoptively transferred T cells! Proud to be part of this stellar collaboration with @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking
Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...
www.biorxiv.org
April 28, 2025 at 10:43 PM
Cool pre-print alert! insight into how neoAg alter trafficking of adoptively transferred T cells! Proud to be part of this stellar collaboration with @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Reposted by LesinskiLab
On April 23, participate in 5 topic-driven sessions at SITC’s ACI: A Focus on Gastrointestinal Cancers program! Gain in-depth education on all aspects of clinical implementation of IO for GI cancers.
Advance your clinical practice and earn free CME: ow.ly/SPaR50VEJbg
@lesinskilab.bsky.social 🧪
Advance your clinical practice and earn free CME: ow.ly/SPaR50VEJbg
@lesinskilab.bsky.social 🧪
April 21, 2025 at 2:29 PM
On April 23, participate in 5 topic-driven sessions at SITC’s ACI: A Focus on Gastrointestinal Cancers program! Gain in-depth education on all aspects of clinical implementation of IO for GI cancers.
Advance your clinical practice and earn free CME: ow.ly/SPaR50VEJbg
@lesinskilab.bsky.social 🧪
Advance your clinical practice and earn free CME: ow.ly/SPaR50VEJbg
@lesinskilab.bsky.social 🧪
www.biorxiv.org/content/10.1...
Excited to share our preprint on comparing Human Primary and metastatic #pancreaticcancer!!!
Excited to share our preprint on comparing Human Primary and metastatic #pancreaticcancer!!!
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Our understanding of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) primarily stems from murine models or primary patient tumors. While metastatic tumors have generally less ...
www.biorxiv.org
April 19, 2025 at 12:38 AM
www.biorxiv.org/content/10.1...
Excited to share our preprint on comparing Human Primary and metastatic #pancreaticcancer!!!
Excited to share our preprint on comparing Human Primary and metastatic #pancreaticcancer!!!
Grateful to #kevinvanderjeught for the opportunity to visit the powerhouse #GIoncology program at #umiami Sylvester cancer center @drjashdatta.bsky.social #nipunmerchant
April 18, 2025 at 1:43 PM
Grateful to #kevinvanderjeught for the opportunity to visit the powerhouse #GIoncology program at #umiami Sylvester cancer center @drjashdatta.bsky.social #nipunmerchant
So very proud of our newly minted Dr. Maggie Phillips! @winshipatemory.bsky.social
She showcased her amazing translational oncology experience in today’s public defense!
She showcased her amazing translational oncology experience in today’s public defense!
April 14, 2025 at 10:29 PM
So very proud of our newly minted Dr. Maggie Phillips! @winshipatemory.bsky.social
She showcased her amazing translational oncology experience in today’s public defense!
She showcased her amazing translational oncology experience in today’s public defense!
Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social
April 12, 2025 at 1:31 AM
Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social
Tremendous talk by Dr. Kailey Oppat @winshipatemory.bsky.social on #FGFR and #IDH interaction with #immune signatures in #cholangiocarcinoma via collab w #carisls @cholangiocarcinoma.bsky.social annual meeting!
April 10, 2025 at 11:15 PM
Tremendous talk by Dr. Kailey Oppat @winshipatemory.bsky.social on #FGFR and #IDH interaction with #immune signatures in #cholangiocarcinoma via collab w #carisls @cholangiocarcinoma.bsky.social annual meeting!
Proud to report our new manuscript describing clinical
Trial results of dual Hsp90/PD1 inhibition in #colorectalcancer. @winship Full article: XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial www.tandfonline.com/doi/full/10....
Trial results of dual Hsp90/PD1 inhibition in #colorectalcancer. @winship Full article: XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial www.tandfonline.com/doi/full/10....
XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial
We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced co...
www.tandfonline.com
March 14, 2025 at 12:59 AM
Proud to report our new manuscript describing clinical
Trial results of dual Hsp90/PD1 inhibition in #colorectalcancer. @winship Full article: XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial www.tandfonline.com/doi/full/10....
Trial results of dual Hsp90/PD1 inhibition in #colorectalcancer. @winship Full article: XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial www.tandfonline.com/doi/full/10....
Very well done article on pancreatic cancer @wsj.com highlighting hope in a devastating disease. Adding the note that fundamental discoveries related to Kras were derived from NIH funding supported by tax dollars well spent.
Pancreatic cancer remains one of the toughest cancers to treat. But newer therapies entering clinical trials are giving doctors hope. on.wsj.com/3Dp4Gfs
March 1, 2025 at 3:30 AM
Very well done article on pancreatic cancer @wsj.com highlighting hope in a devastating disease. Adding the note that fundamental discoveries related to Kras were derived from NIH funding supported by tax dollars well spent.
@immunegirl.bsky.social teaching us all a thing or two about TCRs! @sitcancer.bsky.social winter school master class!
February 13, 2025 at 9:08 PM
@immunegirl.bsky.social teaching us all a thing or two about TCRs! @sitcancer.bsky.social winter school master class!
Stellar talk by @zach-buchwald.bsky.social @winshipatemory.bsky.social at SITC winter school!
Excellent talk by Dr. Zach Buchwald @zach-buchwald.bsky.social from @winshipatemory.bsky.social on immunotherapy in special patient populations. Talks about his amazing work on brain meta and circadian rhythm in immunity!! #CIWS2025 @sitcancer.bsky.social
February 13, 2025 at 9:06 PM
Stellar talk by @zach-buchwald.bsky.social @winshipatemory.bsky.social at SITC winter school!
@chrystalpaulos.bsky.social @winshipatemory.bsky.social knocks it out of the park @sitcancer.bsky.social winter school on the power of CD4 T cells!
February 12, 2025 at 11:18 PM
@chrystalpaulos.bsky.social @winshipatemory.bsky.social knocks it out of the park @sitcancer.bsky.social winter school on the power of CD4 T cells!
Reposted by LesinskiLab
Dr. Yina Huang brings the house down with her AMAZING talk on harnessing synthetic biology to augment next generation cell therapy for cancer patients at Winter School @sitcancer.bsky.social 💥
February 12, 2025 at 7:36 PM
Dr. Yina Huang brings the house down with her AMAZING talk on harnessing synthetic biology to augment next generation cell therapy for cancer patients at Winter School @sitcancer.bsky.social 💥
Reposted by LesinskiLab
We’re thrilled to welcome Dr. Perrine Verdys and Shawez Khan from Denmark and Moldir Konysbekova from Kazakhstan to our 2025 Cancer Immunotherapy Winter School program.
Thanks to all the attendees that made the trip to Austin!
#CIWS2025
Thanks to all the attendees that made the trip to Austin!
#CIWS2025
February 11, 2025 at 8:00 PM
We’re thrilled to welcome Dr. Perrine Verdys and Shawez Khan from Denmark and Moldir Konysbekova from Kazakhstan to our 2025 Cancer Immunotherapy Winter School program.
Thanks to all the attendees that made the trip to Austin!
#CIWS2025
Thanks to all the attendees that made the trip to Austin!
#CIWS2025
Congrats to my brilliant collaborator and friend @chrystalpaulos.bsky.social in this important leadership role!
🎉Congrats to Emory cancer immunologist Chrystal Paulos, PhD, (@chrystalpaulos.bsky.social) who has been named co-leader of the Cancer Immunology Research Program at Winship. ➡️ brnw.ch/21wQB3h
February 11, 2025 at 11:50 AM
Congrats to my brilliant collaborator and friend @chrystalpaulos.bsky.social in this important leadership role!
Reposted by LesinskiLab
BREAKING NEWS: CDC orders mass retraction and revision of submitted research across all science and medicine journals. Banned terms must be scrubbed.
Goes beyond MMWR +other CDC pubs. Applies to research already submitted to top medical journals.
Take a look.
open.substack.com/pub/insideme...
Goes beyond MMWR +other CDC pubs. Applies to research already submitted to top medical journals.
Take a look.
open.substack.com/pub/insideme...
BREAKING NEWS: CDC orders mass retraction and revision of submitted research across all science and medicine journals. Banned terms must be scrubbed.
Any unpublished manuscript mentioning certain topics, including gender and "LGBT," must be pulled or revised.
open.substack.com
February 1, 2025 at 9:20 PM
BREAKING NEWS: CDC orders mass retraction and revision of submitted research across all science and medicine journals. Banned terms must be scrubbed.
Goes beyond MMWR +other CDC pubs. Applies to research already submitted to top medical journals.
Take a look.
open.substack.com/pub/insideme...
Goes beyond MMWR +other CDC pubs. Applies to research already submitted to top medical journals.
Take a look.
open.substack.com/pub/insideme...
Time is running out! Prospective post docs please apply to our event to learn about @winshipatemory.bsky.social
Apply at this link
brnw.ch/21wPrWk
Apply at this link
brnw.ch/21wPrWk
January 29, 2025 at 2:26 AM
Time is running out! Prospective post docs please apply to our event to learn about @winshipatemory.bsky.social
Apply at this link
brnw.ch/21wPrWk
Apply at this link
brnw.ch/21wPrWk
Important lab bench to clinical trial study led by Bassel El-Rayes, MD and many other colleagues on a new combination chemo regimen in pancreatic cancer. Honored to collaborate in this effort!
www.cell.com/cell-reports...
www.cell.com/cell-reports...
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine
Nagaraju et al. have identified that paricalcitol (P) plus hydroxychloroquine (H) potentiates the efficacy of gemcitabine (G) in PDAC. GPH treatment induces ER stress and autophagy with M1 polarization and T cell activation. These findings in PDAC patient-derived data highlight the potential translational impact of GPH therapy in improving clinical outcomes.
www.cell.com
December 26, 2024 at 5:19 PM
Important lab bench to clinical trial study led by Bassel El-Rayes, MD and many other colleagues on a new combination chemo regimen in pancreatic cancer. Honored to collaborate in this effort!
www.cell.com/cell-reports...
www.cell.com/cell-reports...
Join us on March 13-14, 2025, for postdoctoral recruitment event at Winship! Network with mentors and postdocs, and explore Emory's research and career resources. 📅 Apply by January 10, 2025
🔗 Details & Application: brnw.ch/21wPrWk
#PostdocOpportunities #CancerResearch #WinshipResearch
🔗 Details & Application: brnw.ch/21wPrWk
#PostdocOpportunities #CancerResearch #WinshipResearch
Winship Postdoctoral Fellow Recruitment Event
brnw.ch
December 17, 2024 at 3:39 AM
Join us on March 13-14, 2025, for postdoctoral recruitment event at Winship! Network with mentors and postdocs, and explore Emory's research and career resources. 📅 Apply by January 10, 2025
🔗 Details & Application: brnw.ch/21wPrWk
#PostdocOpportunities #CancerResearch #WinshipResearch
🔗 Details & Application: brnw.ch/21wPrWk
#PostdocOpportunities #CancerResearch #WinshipResearch
Reposted by LesinskiLab
We are accepting poster abstract submissions for our upcoming annual conference. This is an opportunity to present late-breaking results, ongoing research projects, and innovative work in cholangiocarcinoma research. Submit an abstract here: cholangiocarcinoma.org/annual-confe...
December 11, 2024 at 3:23 PM
We are accepting poster abstract submissions for our upcoming annual conference. This is an opportunity to present late-breaking results, ongoing research projects, and innovative work in cholangiocarcinoma research. Submit an abstract here: cholangiocarcinoma.org/annual-confe...
December 6, 2024 at 11:59 AM
Outstanding clinical presentation for neoadjuvant cutaneous squamous cell carcinoma by @winshipatemory.bsky.social Dr Michael Lowe #bridge24
December 4, 2024 at 5:06 PM
Outstanding clinical presentation for neoadjuvant cutaneous squamous cell carcinoma by @winshipatemory.bsky.social Dr Michael Lowe #bridge24
Great talk by @jguerriero.bsky.social on macrophages at #Bridge24
December 4, 2024 at 2:36 PM
Great talk by @jguerriero.bsky.social on macrophages at #Bridge24